细胞角蛋白19片段 （Cytokeratin 19 fragment，缩写为Cyfra 21-1）是一种 肺癌 相关的肿瘤标志物，属于中间丝蛋白家族，分子量约为40kD，主要存在于食管癌、肺癌等上皮细胞起源的肿瘤细胞的胞浆中。鳞状上皮（被复上皮）细胞恶化后，构成其胞内主要细胞骨架的中间 ...

质量成功的标志是cyfra21-1的血清浓度迅速下降，反之则表示病灶未完全清除。血清水平下降后又升高，则提示 疾病复发 。但是，cyfra21-1阴性也不能排除存在肺癌的可能。cyfra21-1对各型肺癌诊断的 敏感性 依次为： 鳞癌 ＞ 腺癌 ＞ 大细胞癌 ＞ 小细胞癌 。

Chosen cutoff for cytokeratin 19 fragment antigen (CYFRA 21-1) as a tumor biomarker considerably influences its diagnostic and prognostic usefulness. The aim of the present study is to determine an optimal cutoff value for diagnostic validity of ...

The ability of Cyfra 21-1 to detect different histologic subtypes of lung cancer vs benign lung diseases was assessed through receiver operating characteristic (ROC) curves and comparisons with other tumor markers such as carcinoembryonic antigen, neuron-specific enolase, and squamous cell carcinoma antigen.

CYFRA 21-1 (cytokeratin 19 fragment) has been demonstrated as clinically useful in the prognostication and monitoring of non-small cell lung cancer (NSCLC). Elevated pretreatment levels may be associated with unfavorable prognosis, and decreasing levels during therapy predict an objective response to treatment.

CYFRA 21-1 was identified in 1993 firstly as a valuable marker in lung cancer patients, which could be measured by a sandwich enzyme-linked immunosorbent assay to detect a soluble cytokeratin 19 fragment that is expressed in bronchial epithelium and malignant lung tumors.

Cytokeratin 19 fragments (CYFRA 21-1) proved to be sensitive and valuable biomarkers for estimation of diagnosis, prognosis, and therapy monitoring of lung cancer [6–11]. The CYFRA 21-1 assay is a test that has been developed for the detection of CYFRA 21-1 in serum, especially in patients with non-small cell lung cancer (NSCLC) . However ...

2021年2月2日 · cyfra21-1是非小细胞肺癌最有价值的血清肿瘤标志物，尤其对鳞状细胞癌患者的早期诊断、疗效观察、预后监测有重要意义。 CYFRA21-1也可用于监测横纹肌浸润性膀胱癌的病程，特别是对预计膀胱癌的复发具有较大价值。

cyfra21-1检测可用于膀胱癌的诊断及预后判断。膀胱癌确诊组患者晨尿中cyfra21-1含量显著高于良性膀胱病变组和健康体检组；经治疗（手术、膀胱灌洗、放疗、化疗）后，浅表性膀胱癌组cyfra21-1下降明显，浸润性膀胱癌组患者治疗后较治疗前略有下降 [6] 。

2021年11月5日 · Độ nhạy của CYFRA 21-1 trong ung thư phổi không tế bào nhỏ và trong ung thư phổi tế bào nhỏ lần lượt là 30 - 75% và 20 - 60%. Chỉ số xét nghiệm máu CYFRA 21-1 có ý nghĩa rất lớn trong chẩn đoán bệnh, chẩn đoán tái phát và theo dõi quá trình điều trị bệnh.